Literature DB >> 12647299

Stage specific inhibition of osteoblast lineage differentiation by FGF2 and noggin.

I Kalajzic1, Z Kalajzic, M M Hurley, A C Lichtler, David W Rowe.   

Abstract

Fibroblast growth factor 2 (FGF2) and noggin are two unrelated ligands of two distinctly different signaling pathways that have a similar inhibitory effect on osteoblast differentiation. Because of their differences, we postulated that they probably acted at a different stage within the osteoprogenitor differentiation pathway. This study was performed on primary murine bone cell cultures under conditions where alkaline phosphatase (AP) and type I collagen expression (Col1a1) were observed by day 7 (preosteoblast stage), followed by bone syaloprotein (BSP) at day 11 (early osteoblast) and osteocalcin (OC) by day 15-18 (mature osteoblast stage). FGF2 completely inhibited expression of AP and the mRNA transcript for Col1a1, while noggin showed only a partial inhibition of these markers of preosteoblast differentiation. However, the markers of differentiated osteoblasts (BSP and OC) were completely inhibited in both the FGF2 and noggin treated cultures, suggesting that noggin acts at later point in the osteoprogenitor differentiation pathway than FGF2. To further verify that the inhibition was occurring at a different stage of osteoblasts development, primary cultures derived from transgenic mice harboring segments of the collagen promoter driving green fluorescent protein (GFP) that activate at different levels of osteoblast differentiation were analyzed. Consistent with the endogenous markers, pOBCol3.6GFP and pOBCOL2.3GFP transgene activity was completely inhibited by continuous addition of FGF2, while noggin showed partial inhibition of pOBCol3.6GFP and complete inhibition of the pOBCol2.3GFP transgene. Upon removal of either agent, endogenous and GFP markers of osteoblast differentiation reappeared although at a different temporal pattern. This work demonstrates that FGF2 and noggin can reversibly modulate osteoblast lineage differentiation at different maturational stages. These agents may be useful to enrich for and maintain a population of osteoprogenitor cells at a defined stage of differentiation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12647299     DOI: 10.1002/jcb.10459

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  22 in total

1.  Osteoblast lineage cells expressing high levels of Runx2 enhance hematopoietic progenitor cell proliferation and function.

Authors:  Brahmananda R Chitteti; Ying-Hua Cheng; Drew A Streicher; Sonia Rodriguez-Rodriguez; Nadia Carlesso; Edward F Srour; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 2.  MicroRNA variants as genetic determinants of bone mass.

Authors:  Neha S Dole; Anne M Delany
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

3.  Stage-specific effects of fibroblast growth factor 2 on the differentiation of dental pulp cells.

Authors:  Karen Sagomonyants; Mina Mina
Journal:  Cells Tissues Organs       Date:  2015-03-25       Impact factor: 2.481

4.  * Calvarial Bone Regeneration Is Enhanced by Sequential Delivery of FGF-2 and BMP-2 from Layer-by-Layer Coatings with a Biomimetic Calcium Phosphate Barrier Layer.

Authors:  Gloria Gronowicz; Emily Jacobs; Tao Peng; Li Zhu; Marja Hurley; Liisa T Kuhn
Journal:  Tissue Eng Part A       Date:  2017-11-13       Impact factor: 3.845

5.  Gli3Xt-J/Xt-J mice exhibit lambdoid suture craniosynostosis which results from altered osteoprogenitor proliferation and differentiation.

Authors:  David P C Rice; Elaine C Connor; Jacqueline M Veltmaat; Eva Lana-Elola; Lotta Veistinen; Yukiho Tanimoto; Saverio Bellusci; Ritva Rice
Journal:  Hum Mol Genet       Date:  2010-06-22       Impact factor: 6.150

6.  Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.

Authors:  Yaling Liu; Tulika Sharma; I-Ping Chen; Ernst Reichenberger; Yasuyoshi Ueki; Yumna Arif; Daniel Parisi; Peter Maye
Journal:  Bone       Date:  2018-03-09       Impact factor: 4.398

7.  Proximity-Based Differential Single-Cell Analysis of the Niche to Identify Stem/Progenitor Cell Regulators.

Authors:  Lev Silberstein; Kevin A Goncalves; Peter V Kharchenko; Raphael Turcotte; Youmna Kfoury; Francois Mercier; Ninib Baryawno; Nicolas Severe; Jacqueline Bachand; Joel A Spencer; Ani Papazian; Dongjun Lee; Brahmananda Reddy Chitteti; Edward F Srour; Jonathan Hoggatt; Tiffany Tate; Cristina Lo Celso; Noriaki Ono; Stephen Nutt; Jyrki Heino; Kalle Sipilä; Toshihiro Shioda; Masatake Osawa; Charles P Lin; Guo-Fu Hu; David T Scadden
Journal:  Cell Stem Cell       Date:  2016-08-11       Impact factor: 24.633

8.  Fibroblast growth factor-2 and bone morphogenetic protein-2 have a synergistic stimulatory effect on bone formation in cell cultures from elderly mouse and human bone.

Authors:  Liisa T Kuhn; Guomin Ou; Lyndon Charles; Marja M Hurley; Craig M Rodner; Gloria Gronowicz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-03-26       Impact factor: 6.053

9.  Analysis of αSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing.

Authors:  Brya G Matthews; Danka Grcevic; Liping Wang; Yusuke Hagiwara; Hrvoje Roguljic; Pujan Joshi; Dong-Guk Shin; Douglas J Adams; Ivo Kalajzic
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

10.  Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.

Authors:  C Ren; S Kumar; D Chanda; L Kallman; J Chen; J D Mountz; S Ponnazhagan
Journal:  Gene Ther       Date:  2008-07-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.